MicroVue™ FGF-23 ELISA (Intact)
The MicroVue Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media.
Product Specifications
| Citations | 12 |
|---|---|
| Specimen |
Plasma or Cell Culture Supernatent, 100 µL |
| LLOQ | 0.0015 ng/mL |
| ULOQ | N/A |
| Assay Time | 3.5 hours |
| Cross Reactivity |
None |
Ordering Information
| Catalog Number | 60-6600 |
|---|---|
| Catalog Number (CE) | |
| Size | 96 wells/test |
| Price (USD) | $835.00 |
| Price (EURO) | 740,00 € |
Contact us
| US Phone | +1 (858) 552 1100 |
|---|---|
| EU Phone | +353 (91) 412 474 |
| US Email | contact-us@quidelortho.com |
| EU Email | contact-emea@quidelortho.com |
- Specifications
- Citations
- Certificate of Analysis
Specifications
| Description |
The MicroVue Human FGF-23 (Intact) ELISA Kit is for the measurement of FGF-23 in plasma or cell culture media. |
|---|---|
| Size | 96 wells/test |
| Form |
96 well plate with 12 eight-well strips in a resealable foil pouch |
| Specimen | Plasma or Cell Culture Supernatent, 100 µL |
| Limit of Detection (LOD) | 0.0015 ng/mL |
| Lower Limit of Quantitation (LLOQ) | 0.0015 ng/mL |
| Upper Limit of Quantitation (ULOQ) | N/A |
| Intra Assay | 2.0 - 4.1% |
| Inter Assay | 3.5 - 9.1% |
| Standards | 6 |
| Controls | 2 |
| Sample Values |
N/A |
| Assay Time | 3.5 hours |
| Cross Reactivity |
None |
| Storage |
Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components |
| Background |
Fibroblast growth factor 23 (FGF-23), which is produced by bone cells, is a novel member of a large family of related proteins. Its gene encodes a 251 amino acid protein. The amino-terminal portion of FGF-23 (aa 1-24) is hydrophobic and is likely to serve as a signal peptide allowing its secretion into the blood circulation. Its carboxyl-terminal portion (aa 180-251) shares only limited amino acid homology with other members of the FGF family of proteins. |
Citations
| Title | Year | Applications | Sample Species | Sample | Sample Details |
|---|---|---|---|---|---|
| 2024 | ELISA |
Human |
Serum |
||
| 2024 | ELISA |
Human |
Plasma |
||
|
Role of fibroblast growth factor-23 as an early marker of metabolic bone disease of prematurity |
2024 | ELISA |
Human |
Plasma |
Metabolic bone disease of prematurity |
| 2010 | ELISA |
Human |
Plasma |
||
| 2010 | ELISA |
Human |
Serum |
||
| 2020 | ELISA |
Human |
Plasma |
Chronic Kidney Disease |
|
| 2009 | ELISA |
Human |
Plasma |
||
| 2010 | ELISA |
Human |
Plasma |
||
| 2012 | ELISA |
Human |
Serum |
Chronic Kidney Disease |
|
|
Biological variability of plasma intact and C-terminal FGF23 measurements |
2012 | ELISA |
Human |
Plasma |
|
|
The use of fibroblast growth factor 23 testing in patients with kidney disease. |
2014 | ELISA |
Human |
Plasma |
|
| 2016 | ELISA |
Human |
Plasma |
HIV |
|
| 2016 | ELISA |
Human |
Plasma |
||
| 2016 | ELISA |
Human |
Plasma |
||
| 2018 | ELISA |
Human |
Plasma |
Hypoparathyroidism |
Certificate of Analysis
